OncoDEEP Kit includes all the materials required to perform the comprehensive biomarker testing of solid tumors. The Kit comes with the reagents and probes associated with Twist Capture technology, as well as with the bioinformatics pipeline and our secure, cloud-based MERCURY software to analyze the raw data and access extensive quality control tools. OncoDNA also offers the opportunity to run the sequencing data through its proprietary database and extract patient-specific clinical interpretation reports made available on its OncoKDM online platform. To date, its database counts no less than 4,500,000 genetic variants, 1,150 cancer drugs, and data from 7,000 clinical trials.

Laboratories will have the opportunity to select two types of OncoDEEP Kit: one kit for DNA sequencing only, and another one for the combination of DNA and RNA sequencing.

The OncoDEEP^® comprehensive biomarker test combines NGS with IHC testing to screen for genomic alterations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapies, immunotherapy, hormonal therapy and chemotherapy. The technology is robust and accurate, and the genes of the panel were carefully selected based on their biological and therapeutical relevance.

OncoDEEP^® can be used at diagnosis or at disease progression to identify biomarker-matched targeted therapies or biomarker-stratified clinical trials. It can also provide physicians with extra therapeutic guidance when chemotherapy does not work; when new biomarkers are required for second-line treatment; when cancer comes back; or when patients are diagnosed with highly aggressive cancer or a rare cancer type like a cancer of unknow primary.

The ISO 15189 (Medical laboratories-Requirements for quality and competence), CE-IVD (In vitro diagnostic devices complied to be sold in Europe), ISO 27001 (Information security management) and ISO 13485:2016 (Quality Management System) apply to our OncoDEEP^® comprehensive biomarker test.

Ordering a solution is very simple: Just log in to OncoSHARE and select the biomarker test(s) you are interested in. If you do not have a kit for the collection of the FFPE tissue sample, we will send you one.

It takes about 10 working days from the FFPE tissue sample quality control check to reporting on our clinical decision support system.

For information regarding the price of our OncoDEEP^® biomarker test in your respective country, please contact our sales team.